AUTHORS
Andres Chang, MD,PhD, Alyssa Leal2, Braden James3, Michael Churnetski, BS4, Cecilia Rosand, PA-C5, Simi S Iype, RN6, Jose Antonio Lopez-Saenz7, Colin O'Leary, MA8, Rafi Ahmed, PhD9, Jean Koff, MD, MSc10, Jonathon B. Cohen, MD, MS11
AFFILIATIONS
1 Emory Vaccine Center, Atlanta, Georgia, United States, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
2 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
3 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
4 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
5 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
6 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
7 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
8 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
9 Emory Vaccine Center, Atlanta, Georgia, United States
10 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
11 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
ABSTRACT
Introduction
Patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) have compromised immune systems, increasing their risk of severe and potentially fatal infections. Recently, the United States has experienced several large outbreaks of measles virus (MeV), posing a significant exposure risk to immunosuppressed people. While childhood vaccination against MeV elicits lifelong immunity in otherwise healthy individuals, limited data exist regarding the strength of humoral immunity against MeV after the development and subsequent treatment of B cell malignancies.
Objective
To determine the anti-MeV IgG titers in patients with NHL and CLL across their disease continuum: at diagnosis, on surveillance prior to, during, and after anti-cancer therapy.
Methods
Blood samples from consented patients with NHL and CLL who did not meet criteria for supplemental IgG therapy and 39 healthy individuals without lymphoma (control) were collected from a single academic center and analyzed. Anti-MeV IgG titers were measured by enzyme-linked immunosorbent assay (ELISA) using MeV whole-cell lysate as substrate. Geometric mean titers (GMT) were calculated using a standard curve after background correction and compared using Wilcoxon rank sum and Kruskal-Wallis tests, as appropriate. Clinical data was abstracted from electronic medical records and correlated with anti-MeV IgG titers.
Results
A total of 463 samples from 276 patients were obtained, with 134 samples collected prior to therapy and 329 samples during and/or after treatment. Median age was 66 years, 50.2% were female, 33.3% non-White. In this cohort, 78 patients had an aggressive NHL (aNHL), 139 had chronic lymphocytic leukemia (CLL), and 59 had an indolent NHL (iNHL, 30 follicular lymphoma [FL], and 29 marginal zone lymphoma [MZL]). Patients had a similar median GMT to control (2876AU/mL vs 2494AU/mL, respectively, p=0.82), but a larger GMT range (F test, p<0.005), with 8.6% of samples showing GMT below the minimum GMT found in control (low GMT).
GMT in patients with aNHL did not differ significantly vs control (GMT 2679AU/mL, p=0.8). Based on data from paired and unpaired samples, median GMT remained stable during and after frontline chemoimmunotherapy (p=0.43), and no correlation was observed between IgG titers and years of surveillance after aNHL therapy.
Patients with untreated FL had similar median GMT vs control (3491AU/mL, p=0.96) but median GMT was significantly lower after completion of FL therapy (986AU/mL, p=0.01). Interestingly, patients with untreated MZL showed higher median GMT vs control (7599AU/mL, p=0.02) but this was not observed after completion of MZL therapy (8417AU/mL, p=0.23).
Median GMT for patients with CLL was similar to control (3156AU/mL, p=0.88) and did not change significantly while patients were on surveillance (p=0.47). However, patients who received time-limited treatment regimens showed lower median GMT compared to those on continuous therapy (2397 vs 6149AU/mL, respectively, p=0.006). Most of the GMT decline occurred within 2 years after initiation of time-limited therapy. A trend towards lower GMT was seen with prolonged continuous therapy, but this was not statistically significant (p=0.09). GMT was not associated with cytogenetic abnormalities or IGHV mutation status. Multivariable analysis in the treatment-naïve CLL cohort revealed younger age and years from CLL diagnosis as significant variables associated with lower GMT. Younger age, male sex, years from CLL diagnosis, and receipt of time-limited therapy emerged as significant variables associated with lower GMT in the treated CLL cohort.
Among the 40 patients with low GMT, 15 had aNHL, 20 had CLL, 3 had FL, and 2 had MZL. Twenty percent of patients had treatment-naïve CLL and 12.5% were patients with CLL on continuous therapy. Most (11/15) patients with aNHL had therapy within 2 years.
GMT reported in standardized International Units to determine clinical significance and anti-MeV GMT in patients meeting criteria for treatment with IgG supplementation will be presented.
Conclusion
Patients with B cell malignancies showed variable anti-MeV IgG GMT regardless of lymphoma subtype and prior therapy, with a significant subset of patients showing GMTs that were below the minimum observed in control. Screening for anti-MeV IgG may be warranted, particularly in regions with MeV outbreaks as some patients may benefit from prophylactic IgG supplementation.
DISCLOSURES
Andres Chang, MD,PhD: AbbVie - Current equity holder in publicly-traded company; BeOne - Stock (publicly traded); BMS - Stock (publicly traded); AbbVie - Research Funding; BeOne - Research Funding; BeOne - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)